Among the various targets of protein kinase inhibitors, cyclin-dependent kinases (Cdks) are promising targets for cancer therapeutics because of their important role in cancer cell proliferation via cell cycle dysregulation, which is a hallmark of cancer [3]. Here, WEE1 is linked to cancer.